Get the Stockscreener App
0.015
7.14%
0.0010
Nls Pharmaceutics Ag stock is traded at $0.015, with a volume of 7,635.
It is up +7.14% in the last 24 hours and down -24.24% over the past month.
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.
See More
Previous Close:
$0.014
Open:
$0.0141
24h Volume:
7,635
Relative Volume:
0.17
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+7.14%
1M Performance:
-24.24%
6M Performance:
+25.00%
1Y Performance:
-41.63%
1-Day Range:
$0.014
$0.015
1-Week Range:
$0.014
$0.0169
52-Week Range:
$0.0009
$0.0698
Nls Pharmaceutics Ag Stock (NLSPW) Company Profile
Name
Nls Pharmaceutics Ag
Sector
Industry
Phone
41 44 512 21 50
Address
The Circle 6, Zurich
Compare NLSPW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NLSPW
Nls Pharmaceutics Ag
|
0.015 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Nls Pharmaceutics Ag Stock (NLSPW) Latest News
Custom watchlist performance reports with NLS Pharmaceutics AGTechnical Chart Summary for Momentum Stocks - Newser
Can trapped investors hope for a rebound in NLS Pharmaceutics AGAI Stock Movement Forecast with Accuracy - Newser
What machine learning models say about NLS Pharmaceutics AG Equity WarrantPrice Movement and Market Sentiment Analysis - Newser
Using data models to predict NLS Pharmaceutics AG stock movementFree Low Risk Buy Zone Opportunity Watch - Newser
Will NLS Pharmaceutics AG Equity Warrant stock recover after recent dropWeekly Stock Picks with Trend Confidence - Newser
How to escape a deep drawdown in NLS Pharmaceutics AGConservative Asset Allocation Risk Analysis - Newser
Why NLS Pharmaceutics AG Equity Warrant stock attracts strong analyst attentionMarket Liquidity and Price Flow Analysis - Newser
NLS Pharmaceutics Regains Compliance With Nasdaq Stockholders' Equity Requirement - 富途牛牛
Building trade automation scripts for NLS Pharmaceutics AGFree Wealth Building Stock Market Ideas - Newser
How to escape a deep drawdown in NLS Pharmaceutics AG Equity WarrantPattern Breakout Prediction for Short Term - Newser
Chart based exit strategy for NLS Pharmaceutics AG Equity WarrantAI Screener Based Stock Summary Report - Newser
NLS Pharmaceutics (NASDAQ:NLSP) Rating Increased to Hold at Wall Street Zen - Defense World
Heatmap analysis for NLS Pharmaceutics AG and competitorsFree AI Driven Buy Alert Trade Blueprint - Newser
Is NLS Pharmaceutics AG Equity Warrant still worth holding after the dipForecasting Stock Moves with AI Insights - Newser
Can technical indicators confirm NLS Pharmaceutics AG’s reversalRSI and MACD Signal Summary with Trends - Newser
Volume spikes in NLS Pharmaceutics AG stock – what they meanBuy Signal System Based on Price Action - Newser
Risk adjusted return profile for NLS Pharmaceutics AG Equity Warrant analyzedHigh Probability Trade Outcome Prediction - Newser
Does NLS Pharmaceutics AG Equity Warrant stock pay reliable dividendsTechnical Confirmation System with Signal Alerts - Newser
Developing predictive dashboards with NLS Pharmaceutics AG Equity Warrant dataFree Weekly Setup With 3x Return Potential - Newser
Candlestick signals on NLS Pharmaceutics AG stock todayFree Daily Growth Stock Pick Reports - Newser
Measuring NLS Pharmaceutics AG Equity Warrant’s beta against major indicesFree AI Based High Gain Watchlist Scanner - Newser
Analyzing net buyer seller activity in NLS Pharmaceutics AGMomentum Screener with Buy and Sell Areas - Newser
Long term hold vs stop loss in NLS Pharmaceutics AG Equity WarrantLong-Term Growth Trend Summary With Confidence - Newser
Analyzing NLS Pharmaceutics AG with multi timeframe chartsFree Early Entry Tips With Low Risk Zone - Newser
Can momentum traders help lift NLS Pharmaceutics AG Equity WarrantLow Risk Stock Trade Opportunity Analysis - Newser
Why NLS Pharmaceutics AG stock attracts strong analyst attentionFree Early Entry Tips With Low Risk Zone - Newser
How NLS Pharmaceutics AG stock performs during market volatilityFree High Yield Stock Screening Results - Newser
Analysts Apply Wyckoff Model to NLS Pharmaceutics AG StockWatchlist for Low Risk High Return Stocks Updated - metal.it
When is NLS Pharmaceutics AG stock expected to show significant growthFree Stock Selection - Jammu Links News
Is NLS Pharmaceutics AG a good long term investmentMaximize gains with timely market signals - Jammu Links News
How does NLS Pharmaceutics AG Equity Warrant generate profit in a changing economyBuild wealth with reliable stock picks - Jammu Links News
Should I hold or sell NLS Pharmaceutics AG stock in 2025Achieve breakthrough financial results today - Jammu Links News
Nls Pharmaceutics Ag Stock (NLSPW) Financials Data
There is no financial data for Nls Pharmaceutics Ag (NLSPW). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.24%
3.39%
Cap:
|
Volume (24h):